Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Acute generalized exanthematous pustulosis induced by duloxetine
View through CrossRef
AbstractDuloxetine is a serotonin and norepinephrine reuptake inhibitor. Some rare duloxetine‐induced hypersensitivity skin reactions have been reported. We report a case of acute generalized exanthematous pustulosis potentially induced by duloxetine. Skin pustules appeared 8 days after the introduction of duloxetine. Treatment with topical clobetasol propionate led to gradual remission of the lesions. As there are no cases of duloxetine‐induced acute generalized exanthematous pustulosis(AGEP) in the literature, we did a research in the World Health Organization (WHO) pharmacovigilance database (21 March 2022) and found three cases of duloxetine‐induced AGEP. The French causality assessment score for our case of duloxetine‐induced AGEP was 15 (C2S3). The Naranjo score was 7, indicating a possible correlation between AGEP and the use of duloxetine. This was consistent with the WHO causality score. We inform clinicians of the possibility of AGEP following therapy with duloxetine.
Title: Acute generalized exanthematous pustulosis induced by duloxetine
Description:
AbstractDuloxetine is a serotonin and norepinephrine reuptake inhibitor.
Some rare duloxetine‐induced hypersensitivity skin reactions have been reported.
We report a case of acute generalized exanthematous pustulosis potentially induced by duloxetine.
Skin pustules appeared 8 days after the introduction of duloxetine.
Treatment with topical clobetasol propionate led to gradual remission of the lesions.
As there are no cases of duloxetine‐induced acute generalized exanthematous pustulosis(AGEP) in the literature, we did a research in the World Health Organization (WHO) pharmacovigilance database (21 March 2022) and found three cases of duloxetine‐induced AGEP.
The French causality assessment score for our case of duloxetine‐induced AGEP was 15 (C2S3).
The Naranjo score was 7, indicating a possible correlation between AGEP and the use of duloxetine.
This was consistent with the WHO causality score.
We inform clinicians of the possibility of AGEP following therapy with duloxetine.
Related Results
COMPARISON OF DULOXETINE MONOTHERAPY VERSUS DULOXETINE AND GABAPENTIN COMBINATION THERAPY FOR NEUROPATHIC PAIN RELIEF
COMPARISON OF DULOXETINE MONOTHERAPY VERSUS DULOXETINE AND GABAPENTIN COMBINATION THERAPY FOR NEUROPATHIC PAIN RELIEF
Background: Neuropathic pain is a complex and often refractory condition that significantly impairs quality of life. Pharmacological management remains the cornerstone of treatment...
Duloxetine for the Treatment of Major Depressive Disorder
Duloxetine for the Treatment of Major Depressive Disorder
Background. Existing therapies for depression frequently fail to provide full remission. This report evaluates the efficacy and safety of duloxetine, a dual reuptake inhibitor of s...
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
Introduction
Duloxetine is commonly prescribed to patients with recurrent depressive disorder. Some part of patients in this group do not respond adequately to treatment regimen co...
Duloxetine: An update
Duloxetine: An update
Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has established itself as a versatile therapeutic agent across a spectrum of psychiatric and neurological disorder...
(070) Assessment the Efficacy of Daily Use of Duloxetine in Treatment of Premature Ejaculation: A Prospective Randomized Placebo-Controlled Cross Over Clinical Trial
(070) Assessment the Efficacy of Daily Use of Duloxetine in Treatment of Premature Ejaculation: A Prospective Randomized Placebo-Controlled Cross Over Clinical Trial
Abstract
Introduction
Premature ejaculation is considered to be the most common male sexual disorder, affecting 5% to 40% of sex...
Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report
Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report
AbstractHerein, we report a case of a 73‐year‐old female patient diagnosed with cT4N0M1a lung adenocarcinoma with KRAS G12C mutation, PDL1 < 1% and treated in fourth‐line settin...
Syndrome of inappropriate antidiuretic hormone secretion: a story of duloxetine-induced hyponatraemia
Syndrome of inappropriate antidiuretic hormone secretion: a story of duloxetine-induced hyponatraemia
Hyponatraemia is the most commonly encountered electrolyte abnormality in clinical practice. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) accounts for nearly 60...
Duloxetine increases the effects of levodopa in a rat model of Parkinson's disease
Duloxetine increases the effects of levodopa in a rat model of Parkinson's disease
AbstractBackgroundIn patients with advanced Parkinson's disease, serotonergic and noradrenergic systems act as surrogates for the failing dopaminergic system. Treatment with a sero...